The Application of iPSCs in Tumour Immunotherapy
Abstract Background Tumour immunotherapy holds great promise as a treatment for cancer, which ranks as the second highest cause of mortality worldwide. This therapeutic approach can be broadly categorized into two main types: active immunotherapy and passive or adoptive immunotherapy. Active immunot...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-01-01
|
| Series: | Expert Reviews in Molecular Medicine |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S1462399425100069/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233046417440768 |
|---|---|
| author | Peinan Chen Jian Gao Jianing Feng Hongfei Tao Yongkui Yu Yijing Li Jinlong Liu Shuangshuang Lu Wei Wang |
| author_facet | Peinan Chen Jian Gao Jianing Feng Hongfei Tao Yongkui Yu Yijing Li Jinlong Liu Shuangshuang Lu Wei Wang |
| author_sort | Peinan Chen |
| collection | DOAJ |
| description | Abstract
Background
Tumour immunotherapy holds great promise as a treatment for cancer, which ranks as the second highest cause of mortality worldwide. This therapeutic approach can be broadly categorized into two main types: active immunotherapy and passive or adoptive immunotherapy. Active immunotherapy, such as cancer vaccines, stimulates the patients’ immune system to target tumour cells. On the other hand, adoptive immunotherapy involves supplying in vitro activated immune cells, such as T cells, natural killer cells and macrophages, to the patient to combat the tumour. Induced pluripotent stem cells are extensively utilized in both active and adoptive tumour immunotherapy due to their pluripotency and ease of gene editing. They can be differentiated into various types of immune cells for direct cancer treatment and can also function as tumour vaccines to elicit an immune response against the tumour. Importantly, iPSCs can be leveraged to develop off-the-shelf allogenic immunotherapy products.
Conclusion
This article provides a comprehensive review of the application of iPSCs in tumor immunotherapy, along with a discussion of the opportunities and challenges in this evolving field.
|
| format | Article |
| id | doaj-art-6e344ed24f7a4df6bb538d6ff09f372c |
| institution | Kabale University |
| issn | 1462-3994 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Expert Reviews in Molecular Medicine |
| spelling | doaj-art-6e344ed24f7a4df6bb538d6ff09f372c2025-08-20T12:57:28ZengCambridge University PressExpert Reviews in Molecular Medicine1462-39942025-01-012710.1017/erm.2025.10006The Application of iPSCs in Tumour ImmunotherapyPeinan Chen0Jian Gao1Jianing Feng2Hongfei Tao3Yongkui Yu4Yijing Li5Jinlong Liu6Shuangshuang Lu7https://orcid.org/0000-0002-8144-1830Wei Wang8Department of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaDepartment of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21 Zhengzhou University , Zhengzhou, ChinaDepartment of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaAbstract Background Tumour immunotherapy holds great promise as a treatment for cancer, which ranks as the second highest cause of mortality worldwide. This therapeutic approach can be broadly categorized into two main types: active immunotherapy and passive or adoptive immunotherapy. Active immunotherapy, such as cancer vaccines, stimulates the patients’ immune system to target tumour cells. On the other hand, adoptive immunotherapy involves supplying in vitro activated immune cells, such as T cells, natural killer cells and macrophages, to the patient to combat the tumour. Induced pluripotent stem cells are extensively utilized in both active and adoptive tumour immunotherapy due to their pluripotency and ease of gene editing. They can be differentiated into various types of immune cells for direct cancer treatment and can also function as tumour vaccines to elicit an immune response against the tumour. Importantly, iPSCs can be leveraged to develop off-the-shelf allogenic immunotherapy products. Conclusion This article provides a comprehensive review of the application of iPSCs in tumor immunotherapy, along with a discussion of the opportunities and challenges in this evolving field. https://www.cambridge.org/core/product/identifier/S1462399425100069/type/journal_articleinduced pluripotent stem celliPSC-derived immune cellsiPSC-derived tumour vaccineopportunities and challengestumour immunotherapy |
| spellingShingle | Peinan Chen Jian Gao Jianing Feng Hongfei Tao Yongkui Yu Yijing Li Jinlong Liu Shuangshuang Lu Wei Wang The Application of iPSCs in Tumour Immunotherapy Expert Reviews in Molecular Medicine induced pluripotent stem cell iPSC-derived immune cells iPSC-derived tumour vaccine opportunities and challenges tumour immunotherapy |
| title | The Application of iPSCs in Tumour Immunotherapy |
| title_full | The Application of iPSCs in Tumour Immunotherapy |
| title_fullStr | The Application of iPSCs in Tumour Immunotherapy |
| title_full_unstemmed | The Application of iPSCs in Tumour Immunotherapy |
| title_short | The Application of iPSCs in Tumour Immunotherapy |
| title_sort | application of ipscs in tumour immunotherapy |
| topic | induced pluripotent stem cell iPSC-derived immune cells iPSC-derived tumour vaccine opportunities and challenges tumour immunotherapy |
| url | https://www.cambridge.org/core/product/identifier/S1462399425100069/type/journal_article |
| work_keys_str_mv | AT peinanchen theapplicationofipscsintumourimmunotherapy AT jiangao theapplicationofipscsintumourimmunotherapy AT jianingfeng theapplicationofipscsintumourimmunotherapy AT hongfeitao theapplicationofipscsintumourimmunotherapy AT yongkuiyu theapplicationofipscsintumourimmunotherapy AT yijingli theapplicationofipscsintumourimmunotherapy AT jinlongliu theapplicationofipscsintumourimmunotherapy AT shuangshuanglu theapplicationofipscsintumourimmunotherapy AT weiwang theapplicationofipscsintumourimmunotherapy AT peinanchen applicationofipscsintumourimmunotherapy AT jiangao applicationofipscsintumourimmunotherapy AT jianingfeng applicationofipscsintumourimmunotherapy AT hongfeitao applicationofipscsintumourimmunotherapy AT yongkuiyu applicationofipscsintumourimmunotherapy AT yijingli applicationofipscsintumourimmunotherapy AT jinlongliu applicationofipscsintumourimmunotherapy AT shuangshuanglu applicationofipscsintumourimmunotherapy AT weiwang applicationofipscsintumourimmunotherapy |